The Smallest Reported Malignant Struma Ovarii: A Case Report

被引：4

作者：

Yasutake, Nobuko ^{[1
]}

Noguchi, Hirotsugu ^{[2
]}

Ibayashi, Yuta ^{[3
]}

Nakamura, Hiroaki ^{[4
]}

Tateishi, Kazuki ^{[4
]}

Yuki, Kotaro ^{[1
]}

Shiina, Ryuji ^{[1
]}

Shimajiri, Shohei ^{[2
]}

Fujita, Takuji ^{[1
]}

机构：

[1] Tagawa Municipal Hosp, Dept Gynecol & Obstet, 1700-2 Hoshii, Fukuoka, Fukuoka 8258567, Japan

[2] Univ Occupat & Environm Hlth, Dept Pathol, Kitakyushu, Fukuoka, Japan

[3] Kyushu Univ, Beppu Hosp, Dept Internal Med, Oita, Japan

[4] Tagawa Municipal Hosp, Dept Clin Lab, Fukuoka, Fukuoka, Japan

来源：

CASE REPORTS IN ONCOLOGY | 2018年 / 11卷 / 03期

关键词：

Struma ovarii; Malignant papillary thyroid carcinoma; BRAF;

D O I：

10.1159/000493254

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: Malignant struma ovarii is a rare neoplasm. It is usually asymptomatic and not commonly diagnosed preoperatively. In addition, there is currently no established diagnostic and therapeutic approach for malignant struma ovarii. Case Report: A 66-year-old asymptomatic female was referred to our hospital. Computed tomography showed the presence of a well-defined mass with enhancement in the internal and peripheral areas. The patient underwent total abdominal hysterectomy, bilateral salpingo-oophorectomy, and partial omentectomy. Histopathology revealed the presence of a papillary thyroid carcinoma arising from a 2.5-cm-diameter struma ovarii (malignant struma ovarii). According to the criteria of the International Federation of Gynecology and Obstetrics, the patient had stage IA disease. Subsequently, she underwent a thyroid scan with normal findings. At the 3-month follow-up, the patient was alive, in good clinical condition, and disease free. Conclusion: In this report, we present the smallest malignant struma ovarii reported so far in the literature. Because of the rarity of these tumors and the lack of firm prognostic factors, the treatment decision should be customized for each patient according to the pathological and clinical parameters. (C) 2018 The Author(s) Published by S. Karger AG, Basel

引用

页码：693 / 698

页数：6

共 15 条

[11] BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer [J].

Xing, MZ ;

Westra, WH ;

Tufano, RP ;

Cohen, Y ;

Rosenbaum, E ;

Rhoden, KJ ;

Carson, KA ;

Vasko, V ;

Larin, A ;

Tallini, G ;

Tolaney, S ;

Holt, EH ;

Hui, P ;

Umbricht, CB ;

Basaria, S ;

Ewertz, M ;

Tufaro, AP ;

Califano, JA ;

Ringel, MD ;

Zeiger, MA ;

Sidransky, D ;

Ladenson, PW .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (12) :6373-6379

[12]

Yoo Seung-Chul, 2008, J Gynecol Oncol, V19, P135, DOI 10.3802/jgo.2008.19.2.135

[13]

Young R., 2014, WHO CLASSIFICATION T, P63

[14] Immunohistochemistry is a feasible method to screen BRAF V600E mutation in colorectal and papillary thyroid carcinoma [J].

Zhang, Xiangyan ;

Wang, Lili ;

Wang, Jigang ;

Zhao, Han ;

Wu, Jie ;

Liu, Shuhong ;

Zhang, Lu ;

Li, Yujun ;

Xing, Xiaoming .

EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2018, 105 (01) :153-159

[15] Papillary thyroid cancer located in malignant struma ovarii with omentum metastasis: a case report and review of the literature [J].

Zhu, Yi ;

Wang, Chang ;

Zhang, Guo-Nan ;

Shi, Yu ;

Xu, Shi-Qiang ;

Jia, Shi-Jun ;

He, Rong .

WORLD JOURNAL OF SURGICAL ONCOLOGY, 2016, 14

← 1 2 →